Patents by Inventor Lloyd S. Gray
Lloyd S. Gray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200197516Abstract: The present disclosure provides methods and compositions for inhibiting the proliferation, differentiation, or development of stem cells and cancer stem cells in a patient in need thereof. The methods involve administering to a patient a therapeutically effective amount of an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. The compositions include an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. Specific antagonists such as antibodies and antisense oligonucleotides, and combination therapy with one or more additional anti-cancer agents, are also provided by this disclosure. Such methods, antagonists, and compositions can be useful, for example, in the treatment of cancer.Type: ApplicationFiled: November 15, 2019Publication date: June 25, 2020Applicant: Cavion, Inc.Inventor: Lloyd S. Gray
-
Patent number: 10369120Abstract: The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, wherein R1 is C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; Z is NH, NCH3, O, S, or CH2; Y is NH, O, or CH2 with the proviso that Y and Z are not the same; R2 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; m and n are independently selected from integers ranging from 1-5 with the proviso that m+n=an integer ranging from 2-9; and R3 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy.Type: GrantFiled: November 5, 2015Date of Patent: August 6, 2019Assignee: University of Virginia Patent FoundationInventors: Lloyd S. Gray, Timothy L. Macdonald, Doris M. Haverstick, Jaclyn R. Patterson, William F. McCalmont
-
Publication number: 20180228822Abstract: The present invention provides a method for treating a disease or condition in a mammal which comprises the steps of; administering a therapeutically effective amount of a T type calcium channel inhibitor to effectively slow or stop progression of eukaryotic cells through the S, G2 and M phases of the cell cycle to increase the proportion of the eukaryotic cells in the G1 phase, stopping administration of the T type calcium channel inhibitor for a period of time, and administering a dosage selected from the group consisting of a dosage of at least one chemotherapeutic agent, a dosage of radiation, and combinations thereof, to kill the proportion of eukaryotic cells progressing past the G1 phase of the cell cycle after the stopping of the administration of the T type calcium channel inhibitor.Type: ApplicationFiled: January 12, 2018Publication date: August 16, 2018Inventors: Andrew J. Krouse, Lloyd S. Gray, Timothy MacDonald, Joel Linden
-
Patent number: 9427429Abstract: The present invention provides a method for imaging a disease or condition in a mammal which includes the steps of; administering a therapeutically effective amount of a cell cycle inhibitor to effectively stop proliferation of eukaryotic cells at a cell cycle checkpoint between the G1 and S phase, stopping administration of the cell cycle inhibitor for a period of time, administering a marker to the mammal and imaging the mammal.Type: GrantFiled: February 28, 2011Date of Patent: August 30, 2016Assignee: Tau Therapeutics LLCInventor: Lloyd S. Gray
-
Publication number: 20160136115Abstract: The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, wherein R1 is C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; Z is NH, NCH3, O, S, or CH2; Y is NH, O, or CH2 with the proviso that Y and Z are not the same; R2 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; m and n are independently selected from integers ranging from 1-5 with the proviso that m+n=an integer ranging from 2-9; and R3 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy.Type: ApplicationFiled: November 5, 2015Publication date: May 19, 2016Inventors: Lloyd S. Gray, Timothy L. Macdonald, Doris M. Haverstick, Jaclyn R. Patterson, William F. McCalmont
-
Patent number: 9212127Abstract: The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, wherein R1 is C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; Z is NH, NCH3, O, S, or CH2; Y is NH, O, or CH2 with the proviso that Y and Z are not the same; R2 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; m and n are independently selected from integers ranging from 1-5 with the proviso that m+n=an integer ranging from 2-9; and R3 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy.Type: GrantFiled: August 22, 2005Date of Patent: December 15, 2015Assignee: University of Virginia Patent FoundationInventors: Lloyd S. Gray, Timothy L. MacDonald, Doris M. Haverstick, Jaclyn R. Patterson, William F. McCalmont
-
Publication number: 20150355163Abstract: Presented herein are compounds that inhibit T-type Ca2+ channel activity in a cell when the cell membrane potential is about ?90 mV. Preferred compounds inhibit T-type Ca2+ channel activity with an IC50 of 10 ?M or less at a membrane potential of about ?90 mV. Preferred compounds show selectivity for inhibiting T-type Ca2+ channel activity at about ?90 mV, relative to inhibition of T-type Ca2+ channel activity at about ?30 mV to ?60 mV, of 10:1 or less. Also provided are methods for identifying compounds that inhibit T-type Ca2+ channel activity in a cell when the cell membrane potential is about ?90 mV, and compounds identified by such methods.Type: ApplicationFiled: January 10, 2014Publication date: December 10, 2015Inventors: Lloyd S. Gray, Timothy MacDonald
-
Publication number: 20130064814Abstract: The present disclosure provides methods and compositions for inhibiting the proliferation, differentiation, or development of stem cells and cancer stem cells in a patient in need thereof. The methods involve administering to a patient a therapeutically effective amount of an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. The compositions include an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. Specific antagonists such as antibodies and antisense oligonucleotides, and combination therapy with one or more additional anti-cancer agents, are also provided by this disclosure. Such methods, antagonists, and compositions can be useful, for example, in the treatment of cancer.Type: ApplicationFiled: September 11, 2012Publication date: March 14, 2013Inventor: Lloyd S. Gray
-
Publication number: 20120321561Abstract: The present invention provides a method for imaging a disease or condition in a mammal which includes the steps of; administering a therapeutically effective amount of a cell cycle inhibitor to effectively stop proliferation of eukaryotic cells at a cell cycle checkpoint between the G1 and S phase, stopping administration of the cell cycle inhibitor for a period of time, administering a marker to the mammal and imaging the mammal.Type: ApplicationFiled: February 28, 2011Publication date: December 20, 2012Applicant: TAU THERAPEUTICS LLCInventor: Lloyd S. Gray
-
Publication number: 20120264804Abstract: The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug, wherein the T type calcium channel inhibitor blocks a splice variant of an ?1H isoform of T type calcium channels.Type: ApplicationFiled: October 6, 2011Publication date: October 18, 2012Applicant: University of Virginia Patent FoundationInventors: Lloyd S. Gray, Doris M. Haverstick
-
Publication number: 20120088807Abstract: The present invention provides a method for treating a disease or condition in a mammal which comprises the steps of; administering a therapeutically effective amount of a T type calcium channel inhibitor to effectively slow or stop progression of eukaryotic cells through the S, G2 and M phases of the cell cycle to increase the proportion of the eukaryotic cells in the G1 phase, stopping administration of the T type calcium channel inhibitor for a period of time, and administering a dosage selected from the group consisting of a dosage of at least one chemotherapeutic agent, a dosage of radiation, and combinations thereof, to kill the proportion of eukaryotic cells progressing past the G1 phase of the cell cycle after the stopping of the administration of the T type calcium channel inhibitor.Type: ApplicationFiled: June 4, 2010Publication date: April 12, 2012Applicant: TAU THERAPEUTICS LLCInventors: Andrew J. Krouse, Lloyd S. Gray, Timothy MacDonald, Joel Linden
-
Publication number: 20100222406Abstract: The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug, wherein the T type calcium channel inhibitor has a structure represented by Formula (I): Formula (I), wherein R1 is selected from the group consisting of C1-C4 alkyl, hydroxy and C1-C4 alkoxy; X is selected from the group consisting of N and CH; Z is selected from the group consisting of NH, O, S and CH2; R2 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy; and R3 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy.Type: ApplicationFiled: January 14, 2010Publication date: September 2, 2010Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Lloyd S. Gray, Doris M. Haverstick
-
Publication number: 20090234019Abstract: The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, wherein R1 is C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; Z is NH, NCH3, O, S, or CH2; Y is NH, O, or CH2 with the proviso that Y and Z are not the same; R2 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; m and n are independently selected from integers ranging from 1-5 with the proviso that m+n=an integer ranging from 2-9; and R3 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy.Type: ApplicationFiled: August 22, 2005Publication date: September 17, 2009Inventors: Lloyd S. Gray, Timothy L. MacDonald, Doris M. Haverstick, Jaclyn R. Patterson, William F. McClamont
-
Publication number: 20080194669Abstract: The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug, wherein the T type calcium channel inhibitor has a structure represented by Formula (I): Formula (I), wherein R1 is selected from the group consisting of C1-C4 alkyl, hydroxy and C1-C4 alkoxy; X is selected from the group consisting of N and CH; Z is selected from the group consisting of NH, O, S and CH2; R2 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy; and R3 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy.Type: ApplicationFiled: August 22, 2005Publication date: August 14, 2008Inventors: Lloyd S. Gray, Doris M. Haverstick
-
Publication number: 20080160009Abstract: The invention provides a pharmaceutical composition comprising an antibody that specifically binds to a Cav3 isoform or its ?25 splice variants thereof. The present invention also relates to compositions and methods for inhibiting cancer cell proliferation, preventing, treating and/or controlling cancer and/or related disorders in a patient by administering to the patient a therapeutically effective amount of the T type calcium channel selective inhibitor. A preferred T type calcium channel selective inhibitor is mibefradil.Type: ApplicationFiled: February 11, 2005Publication date: July 3, 2008Inventors: Lloyd S. Gray, Timothy L. MacDonald
-
Patent number: 6946475Abstract: The present invention is directed to compounds useful as cancer cell inhibitors, compositions containing such compounds and methods for inhibiting proliferation of electrically non-excitable cells.Type: GrantFiled: April 7, 2000Date of Patent: September 20, 2005Assignee: University of Virginia Patent FoundationInventors: Lloyd S. Gray, Timothy L. Macdonald, Doris Haverstick, Tiffany N. Heady
-
Patent number: 6413967Abstract: The present invention provides methods for screening for voltage gated (VG)-selective inhibitors, novel VG-selective inhibitors, compositions containing the same, methods for inhibiting calcium entry into electrically non-excitable cells with said VG-selective inhibitors, methods for preventing proliferation of electrically non-excitable cells with said VG-selective inhibitors as well as methods of treating autoimmune diseases, preventing graft rejections, preventing apoptosis and treating cancer with the same.Type: GrantFiled: March 30, 1995Date of Patent: July 2, 2002Assignee: The University of Virginia Patents FoundationInventors: Lloyd S. Gray, Doris M. Haverstick, John J. Densmore, Gabor Szabo